News About: Pharm. Industry
Countdown of Alexion, developer of Soliris, to enter the domestic market
Another global pharmaceutical company is confirmed to consider a market entry to Korea.
The company is Alexion Pharmaceuticals, domestically well-known as a developing company of ‘Soliris, a PNH(paroxysmal nocturnal ...
Ilyang Pharmaceutical launches ‘Supect’ as a primary treatment of leukemia‘Supect(generic name: radotinib),’ the Asia’s first leukemia treatment developed by Ilyang Pharmaceutical(CEO Dong-yeon Kim), will be launched as the ‘primary treatment’ on the ...
|
Significant achievement of the Yuhan anb Boehringer duo in the outpatient prescription marketWhile the domestic outpatient prescription market has been depressed since the pharmaceutical price cuts in 2012, the top company ranking has met many changes.
Some of the top ...
|
Celltrion achieves export declaration record of KRW 600 billion with RemsimaThe last year’s export declaration record of ‘Remsima(rheumatoid arthritis treatment),’ a Celltrion’s biosimilar, was observed to be KRW 600 billion increased by approximately 5...
|
Strong ‘womanpower’ among multinational pharmaceutical companies
‘Womanpower’ is getting stronger among multinational pharmaceutical companies. Appointment of women CEOs has continued once again this year.
As CEO Eun-young Kim of Allergan Korea was appointed to the regional direct...
MSD’s truth about the Januvia agreement breakdownSince the consigned pharmaceutical company of ‘Januvia(generic name: sitagliptin),’ a DPP-4 inhibitor recording KRW 150 billion annual sales with its single and complex drugs, w...
|
3 mega-blockbuster products recording annual KRW 1 trillion sales in pharmaceutical industry
It was estimated there will be the total 3 mega-blockbuster products exceeding annual KRW 100 billion sales in the pharmaceutical industry last year.
KRW 100 billion sales from a single product are as equivalent as a...
Dong-A ST creates antidiabetic agent combining ‘Suganon-Actos’Dong-A ST has started to develop a complex combining Suganon(evogliptin), a domestic DPP-4-inhibitor treatment, and Actos(pioglitazone, Takeda Pharmaceutical), a TZD-type drug.
...
|
Multinational pharmaceutical companies being ignored by domestic ones as ignoring ‘win-win’
There have been a number of issues about cooperation of domestic pharmaceutical companies with multinational pharmaceutical companies, such as ‘co-marketing’ and ‘co-promotion.’
As most pharmaceutical companies estab...
Pfizer wins the final nullification trial on the use patent of LyricaPfizer has won the final nullification trial filed by generic companies on the use patent of ‘Lyrica(generic name: pregabalin).’ The Supreme Court made a final ruling the use pa...
|
